PTC Inc (PTC) reports robust growth in ARR and free cash flow, while divesting non-core businesses to focus on its ...

Among sectors, their biggest 'conviction' as regards India is on the defence sector, where Goldman Sachs believes PTC ...

PTC (NASDAQ: PTC) today reported financial results for its fourth fiscal quarter and full fiscal year ended September 30, 2025.

Investing.com - PTC (NASDAQ: PTC) reported third quarter EPS of $3.47, $1.20 better than the analyst estimate of $2.27. Revenue for the quarter came in at $894M versus the consensus estimate of ...

The biopharmaceutical company posted revenue of $211 million in the period, which also beat Street forecasts. Five analysts surveyed by Zacks expected $175.6 million. PTC Therapeutics expects ...

Fintel reports that on October 30, 2025, Rosenblatt maintained coverage of PTC (NasdaqGS:PTC) with a Buy recommendation.

PTC Therapeutics' Q3 earnings highlight Sephience's strong global launch, healthy revenue, and narrowed 2025 guidance.

PTC Therapeutics (PTCT) reported $211.01 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 7.2%. EPS of $0.20 for the same period compares to -$1.39 a ...

PTC (NASDAQ: PTC) has outperformed the market over the past 10 years by 7.24% on an annualized basis producing an average annual return of 20.37%. Currently, PTC has a market capitalization of $24.39 ...

Goldman Sachs turns bullish on PTC Industries, calling it a titanium powerhouse in India’s emerging aerospace ecosystem with ...

PTC India Financial shares rallied on the back of a healthy set of numbers in the September quarter of financial year 2026 ...